Hepatitis C: New Treatments in the Pipeline - CD8 T cells - The Body

30
Table 7 . Albuferon vs . Standard of Care In Treatment-Naïve People With HCV
Genotype 1 (N=458)
Regimen SVR Discontinued for Adverse Events
Low-dose, every 2 weeks, Albuferon 900μg + RBV 58.5% 9.3%
High-dose, every 2 weeks, Albuferon 1200μg + RBV 55.5% 18.2%
High-dose, every 4 weeks, Albuferon 1200μg + RBV 50.9% 12.1%
Control, PEG-INF + RBV 57.9% 6.1%
Source:
Zeuzem S, Yoshida EM, Benhamou Y, et al. (abstract 180) Sustained virologic response rates with albinterferon alfa-2b plus
ribavirin treatment in IFN-naïve, chronic hepatitis C genotype 1 patients. 58th Annual Meeting of the American Association
for the Study of Liver Diseases. Boston, MA. November 2–6, 2007.
Table 8 . Albuferon in Non-Responders to Pegylated Interferon Plus Ribavirin
Regimen SVR
Low-dose, every 2 weeks, Albuferon 900μg + RBV 30%
High-dose, every 2 weeks, Albuferon 1200μg + RBV 13%
High-dose, every 4 weeks, Albuferon 1200μg + RBV 25%
Higher-dose, every 2 weeks, Albuferon 1500μg + RBV 9%
Highest-dose, every 2 weeks, Albuferon 1800μg + RBV 17%
Source:
Nelson D, Rustgi V, Balan V, et al. (abstract 51) Sustained virologic response with albinterferon alfa-2b plus ribavirin
treatment in prior interferon therapy nonresponders. 58th Annual Meeting of the American Association for the Study of Liver
Diseases. Boston, MA. November 4, 2007.
• Locteron-interferon
Locteron-interferon is a continuously released formulation of interferon alfa-2b, currently in
phase IIa. SELECT-1 is assessing safety, tolerability, activity, and pharmacokinetics of Locteron,
given every two weeks, plus daily ribavirin, in 32 treatment-naïve people with HCV genotype 1.
Early results have been presented (see Table 9. Week 12 Results from SELECT-1, page 31).
A single, unspecified serious adverse event occurred; otherwise, adverse events were mild,
although weakness, joint and muscle pain, and headache were common. More data will be
presented at the end of 2008.